Anti-Inflammatory Effects of Time-Restricted Feeding

Psoriasis Clinical Trial

Official title:

Pilot Study to Explore the Anti-Inflammatory Effects of Time-Restricted Feeding

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04728165
• Other study ID #: 10000149
• Secondary ID: 000149-H
• Status: Completed
• Start date: June 9, 2021
• Est. completion date: July 28, 2023

Study information

• Verified date: December 4, 2023
• Source: National Institutes of Health Clinical Center (CC)
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Background:

Time-restricted feeding (TRF) means that a person eats only during certain hours of the day. In other studies, researchers have found that fasting can improve immune system function in healthy people. They want to see if TRF has the same effect on people with psoriasis.

Objective:

To test whether TRF can change metabolism and decrease some markers of inflammation in the blood of people with mild to moderate psoriasis.

Eligibility:

Males ages 18 to 80 with mild to moderate active psoriasis, and healthy volunteers

Design:

Participants will be screened with a medical history and medicine review. They will have a physical exam and blood tests. Their skin will be examined. They will have a nutritional evaluation. Their resting energy expenditure will be measured. For this, a clear plastic ventilation hood will be placed over the head for a short time.

Participants will stay at the NIH Clinical Center for 4 1/2 days. They can watch TV, do work, do schoolwork, and other quiet activities.

A small sensor will be placed under participants skin to measure blood glucose.

For part of the study, participants will be housed in a small room called a metabolic chamber. They will wear a heart monitor.

Participants will walk on a treadmill for 30 minutes each day at a comfortable speed.

For 3 days, participants will eat all their daily calories between 8 am and 2 pm. They will fast for the other 18 hours of the day. They can drink water.

Participants will complete mixed meal tests. They will drink a liquid meal for breakfast. Then they will give blood samples via intravenous (IV) catheter.

Participation will last for 5 days....

Description:

Study Description:

Fasting and caloric restriction interventions have anti-inflammatory effects, although the underling regulatory controls are poorly characterized. This pilot study will explore transcriptional profiles in various leukocyte populations comparing the effect of time restricted feeding (TRF - 6-Hr feeding/18-Hr fast) to a more conventional dietary regimen (12-Hr feeding/12Hr fast). These regulatory effects will be evaluated in an inflammatory disease (psoriasis) in response to TRF and by comparing the relative response comparing the psoriasis population to a matched TRF control group.

Objectives:

1. Evaluate the effect of TRF on Th17 immunological signatures.

2. Compare the role of TRF on chromatin remodeling on CD4+ T cells, monocytes and neutrophils comparing control and

psoriatic subjects.

3. Evaluate the effect of TRF on glucose and insulin metabolism and overall metabolic flexibility.

Endpoints:

The primary outcome will be the change in the secretion of IL-17 from activated CD4+ T cells from baseline to the end of TRF as a measure of biological reprograming in the psoriasis group and to assess the change in IL-17 release comparing the effects of TRF in the control versus psoriasis groups.

Secondary outcomes are:

1. Evaluate the effect of TRF on chromatin signatures of gene activation (ATACseq) and gene silencing (H3K9me3).

2. Explore the effect of TRF on low-density granulocytes, neutrophils and monocytes.

3. Evaluate whether TRF improves 24-hour glucose levels, glycemic excursions during a meal test and modulate sleeping

and feeding metabolic flexibility as defined by the change in sleeping respiratory exchange ratio from the daytime. (24-hr

substrate oxidation as defined by the averaged RER)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 27
• Est. completion date: July 28, 2023
• Est. primary completion date: July 28, 2023
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 80 Years

Eligibility

• INCLUSION CRITERIA:

Individuals must meet the inclusion criteria listed below in order to be eligible to participate in the study.

• Males between the ages of 18 and 80 with mild to moderate active psoriasis by PASI score for inclusion in psoriasis group

• Age (plus or minus 10 yrs) and BMI (plus or minus 5 kg/m^2) matched control male subjects for inclusion in the control group.

• Ability to provide informed consent

• Willingness and ability to participate in study procedures

EXCLUSION CRITERIA:

• Severe psoriasis by PASI (Psoriasis Area and Severity Index) score > 12

• Treatment with systemic biologic immune modifying agents within the last 2 months.

• Currently on treatment for allergies or other inflammatory diseases.

• Has taken Vitamin B or tryptophan supplementation within 2 weeks of participation.

• Unwillingness/inability to provide informed consent.

• Individuals with known history of type 1 and 2 diabetes mellitus or other metabolic conditions that would interfere with study parameters including chronic kidney disease, chronic liver disease, history of hypoglycemia

• On treatment with medication that would interfere with study parameters including anti-hyperglycemic medications, systemic steroids, adrenergic-stimulating agents, other medications known to affect sleep, circadian rhythms or metabolism.

• Caffeine in excess of three 8 oz cups per day.

• Factors that affect circadian rhythm including individuals who perform overnight shift work, irregular sleep and/ or eating schedules, regularly fast for more than 15 hours/ day

• Regular use of tobacco product within last 3 months.

• Consuming more than 3 servings of alcohol/ day

• Engaged in competitive sports training

• Moderate to severe claustrophobia

• Unstable weight with more than 5% body weight change in last 3 months

• Food allergies or intolerances or dietary patterns that would prohibit consumption of the metabolic diet or mixed meal test.

Related Conditions & MeSH terms

• Inflammation
• Psoriasis
• Systemic Inflammation

Locations

Country	Name	City	State
United States	National Institutes of Health Clinical Center	Bethesda	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	change in the secretion of IL-17 from activated CD4+ T cells from baseline to the end of TRF	The primary outcome will be the change in the secretion of IL-17 from activated CD4+ T cells from baseline to the end of TRF as a measure of biological reprograming in the psoriasis group and to assess the change in IL-17 release comparing the effects of TRF in the control versus psoriasis groups.	3 years
Secondary	Evaluate the effect of TRF on chromatin signatures of gene activation (ATACseq) and gene silencing (H3K9me3)	Evaluate the effect of TRF on chromatin signatures of gene activation (ATACseq) and gene silencing (H3K9me3)	5 years
Secondary	Explore the effect of TRF on low-density granulocytes, neutrophils and monocytes	Explore the effect of TRF on low-density granulocytes, neutrophils and monocytes.	5 years
Secondary	Evaluate whether TRF improves 24-hour glucose levels, glycemic excursions during a meal test and modulate sleeping and feeding metabolic flexibility as defined by the change in sleeping respiratory exchange ratio from the daytime. (24-hr substra...	Evaluate whether TRF improves 24-hour glucose levels, glycemic excursions during a meal test and modulate sleeping and feeding metabolic flexibility as defined by the change in sleeping respiratory exchange ratio from the daytime. (24-hr substrate oxidation as defined by the averaged RER)	4 years

External Links

•   NIH Clinical Center Detailed Web Page